Investors waiting for M&A activity
in the controversial purified pharma-grade fish oil market got some
Tuesday morning, but probably not with the company they were expecting. AstraZeneca (NYSE:AZN) announced the acquisition of third-in-line pharma-grade fish oil company Omthera (Nasdaq:OMTH)
for up to $443 million in total consideration. Although the deal offers
a significant premium to where Omthera was trading and makes sense as a
platform/portfolio addition, it's not exactly a risky high-value deal
for AstraZeneca.
To read the full article, please click here:
http://www.investopedia.com/stock-analysis/052813/astrazeneca-looks-fish-oil-round-out-its-cardio-portfolio-azn-omth-amrn.aspx
No comments:
Post a Comment